Keywords: HIV; Injectable pre-exposure prophylaxis; Cabotegravir; PrEP; HIV prevention EN HIV Injectable pre-exposure prophylaxis Cabotegravir PrEP HIV prevention 212 214 3 02/14/23 20230201 NES 230201 In December 2021, the U.S. Food and Drug Administration approved the first injectable, long-acting HIV pre-exposure prophylaxis (PrEP) medication, cabotegravir, an integrase strand transfer inhibitor [[1]]. Although injectable PrEP may be an appropriate choice for many, including those with significant renal disease, it is contraindicated for patients taking rifampicin, rifapentin, carbamezapine, oxcarbamezapine, phenytoin, or phenobarbital due to drug interactions, and should not be taken concomitantly with these medications [[4]]. In addition to increasing PrEP knowledge and access, normalizing patient-provider conversations about PrEP can improve provider comfortability in prescribing PrEP and reduce the stigma associated with PrEP usage. [Extracted from the article]